Establishes the breakthrough therapies research fund. Provides that a drug, biological product, or medical device that has been designated as a breakthrough therapy under federal law may be made available to a qualified patient and offered by a physician as a part of the patient's medical treatment. Specifies that a civil or criminal cause of action is not created against a manufacturer or health care provider for any harm to a qualified patient resulting from use of an investigational drug, biological product, or device.

Statutes affected:
Introduced House Bill (H): 16-18-2-143, 16-42-26-2, 16-42-26-5, 25-22.5-1-2.1